Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

GM-CSF agonist

DRUG CLASS:

GM-CSF agonist

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	talimogene laherparepvec Sensitive: A2 - Guideline talimogene laherparepvec Sensitive : A2	talimogene laherparepvec Sensitive: A2 - Guideline talimogene laherparepvec Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	PD1 inhibitor + talimogene laherparepvec Resistant: A2 - Guideline PD1 inhibitor + talimogene laherparepvec Resistant : A2	PD1 inhibitor + talimogene laherparepvec Resistant: A2 - Guideline PD1 inhibitor + talimogene laherparepvec Resistant : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	ipilimumab + talimogene laherparepvec Sensitive: A2 - Guideline ipilimumab + talimogene laherparepvec Sensitive : A2	ipilimumab + talimogene laherparepvec Sensitive: A2 - Guideline ipilimumab + talimogene laherparepvec Sensitive : A2
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	talimogene laherparepvec Sensitive: A2 - Guideline talimogene laherparepvec Sensitive : A2	talimogene laherparepvec Sensitive: A2 - Guideline talimogene laherparepvec Sensitive : A2
No biomarker	Melanoma	No biomarker	Melanoma	ONCOS-102 Sensitive: B - Late Trials ONCOS-102 Sensitive : B	ONCOS-102 Sensitive: B - Late Trials ONCOS-102 Sensitive : B
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	CG0070 Sensitive: B - Late Trials CG0070 Sensitive : B	CG0070 Sensitive: B - Late Trials CG0070 Sensitive : B
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	nivolumab + ipilimumab + talimogene laherparepvec Sensitive: C2 – Inclusion Criteria nivolumab + ipilimumab + talimogene laherparepvec Sensitive : C2	nivolumab + ipilimumab + talimogene laherparepvec Sensitive: C2 – Inclusion Criteria nivolumab + ipilimumab + talimogene laherparepvec Sensitive : C2
BRAF V600	Melanoma	BRAF V600	Melanoma	ipilimumab + talimogene laherparepvec Resistant: C3 – Early Trials ipilimumab + talimogene laherparepvec Resistant : C3	ipilimumab + talimogene laherparepvec Resistant: C3 – Early Trials ipilimumab + talimogene laherparepvec Resistant : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	atezolizumab + talimogene laherparepvec Sensitive: C3 – Early Trials atezolizumab + talimogene laherparepvec Sensitive : C3	atezolizumab + talimogene laherparepvec Sensitive: C3 – Early Trials atezolizumab + talimogene laherparepvec Sensitive : C3
HR positive	Leiomyosarcoma	HR positive	Leiomyosarcoma	nivolumab + talimogene laherparepvec Sensitive: C3 – Early Trials nivolumab + talimogene laherparepvec Sensitive : C3	nivolumab + talimogene laherparepvec Sensitive: C3 – Early Trials nivolumab + talimogene laherparepvec Sensitive : C3
STING expression	Melanoma	STING expression	Melanoma	talimogene laherparepvec Resistant: D – Preclinical talimogene laherparepvec Resistant : D	talimogene laherparepvec Resistant: D – Preclinical talimogene laherparepvec Resistant : D